NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, told shareholders at its annual meeting today that fiscal 2007 – the year ended July 31, 2007 – was a transformative year in which steps taken will benefit operations in fiscal 2008 and beyond.
